Current Treatments to Control African Trypanosomiasis and One Health Perspective

• Type: Another Publication in an International Scientific Journal
• Date: 2022

Authors

Venturelli, A (Author) Other; Tagliazucchi, L (Author) Other; Lima, C (Author) Other; Venuti, F (Author) Other; Malpezzi, G (Author) Other; Magoulas, GE (Author) Other; Santarem, N (Author) Other; Calogeropoulou, T (Author) Other; Anabela Cordeiro da Silva (Author) FFUP; Costi, MP (Author) Other

Journal

Title: Microorganisms

Vol. 13

Final page: 1298

Publisher: MDPI

Indexing

ISI Web of Knowledge - 0 Citations

Scopus - 0 Citations

Other information

Authenticus ID: P-00W-W2M

DOI: 10.3390/microorganisms10071298

Abstract (EN): Human African Trypanosomiasis (HAT, sleeping sickness) and Animal African Trypanosomiasis (AAT) are neglected tropical diseases generally caused by the same etiological agent, Trypanosoma brucei. Despite important advances in the reduction or disappearance of HAT cases, AAT represents a risky reservoir of the infections. There is a strong need to control AAT, as is claimed by the European Commission in a recent document on the reservation of antimicrobials for human use. Control of AAT is considered part of the One Health approach established by the FAO program against African Trypanosomiasis. Under the umbrella of the One Health concepts, in this work, by analyzing the pharmacological properties of the therapeutic options against Trypanosoma brucei spp., we underline the need for clearer and more defined guidelines in the employment of drugs designed for HAT and AAT. Essential requirements are addressed to meet the challenge of drug use and drug resistance development. This approach shall avoid inter-species cross-resistance phenomena and retain drugs therapeutic activity.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 24